<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00653185</url>
  </required_header>
  <id_info>
    <org_study_id>01-06-TL-SYR-472-007</org_study_id>
    <secondary_id>U1111-1183-0302</secondary_id>
    <nct_id>NCT00653185</nct_id>
  </id_info>
  <brief_title>Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate Weekly Treatment With SYR-472 in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy, safety and tolerability of SYR-472,&#xD;
      once daily (QD), in subjects with Type 2 Diabetes Mellitus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes mellitus is a complex metabolic disorder characterized by abnormal insulin&#xD;
      secretion and glucose homeostasis, resulting from impaired pancreatic beta-cell function and&#xD;
      insulin resistance in target tissues. The worldwide prevalence of type 2 diabetes mellitus is&#xD;
      reaching epidemic proportions, and the total number of cases is expected to reach 221 million&#xD;
      by 2010. The high incidence of the disease and its associated complications places a&#xD;
      significant burden on healthcare systems.&#xD;
&#xD;
      The primary risk factor for the development of type 2 diabetes mellitus is obesity and its&#xD;
      associated insulin resistance. Insulin resistance is characterized by an impaired response to&#xD;
      the physiologic effects of insulin and leads to decreased cellular glucose uptake, increased&#xD;
      hepatic gluconeogenesis, and a compensatory increase in insulin secretion that contributes to&#xD;
      beta-cell exhaustion. Therefore in the insulin-resistant state, blood glucose and insulin&#xD;
      levels are increased. The relationship between improved glycemic control in patients with&#xD;
      type 2 diabetes mellitus and the delay or prevention of comorbidities has been reported in&#xD;
      the Diabetes Control and Complications Trial and the United Kingdom Prospective Diabetes&#xD;
      Study. Therefore, reduction of persistent hyperglycemia is the highest priority in treating&#xD;
      this disease.&#xD;
&#xD;
      Diet and exercise are important and effective measures for maintaining glycemic control in&#xD;
      individuals with insulin resistance, impaired glucose tolerance, and type 2 diabetes&#xD;
      mellitus, particularly in the early stages of disease progression. In cases where diet and&#xD;
      exercise alone fail to adequately maintain glycemic control, oral antidiabetic drugs are&#xD;
      typically used. Combination oral therapy and eventually insulin are usually required to&#xD;
      maintain lower blood glucose levels but can result in adverse effects including hypoglycemia&#xD;
      and weight gain. Therefore, novel safe and effective antidiabetic therapies are needed.&#xD;
&#xD;
      Dipeptidyl peptidase-4 is a ubiquitous aminopeptidase that is widely expressed in many&#xD;
      tissues; it is thought to be primarily responsible for the in vivo degradation of at least&#xD;
      two gut-derived incretin hormones, namely glucagon-like peptide-1 and glucose-dependent&#xD;
      insulinotropic peptide, which are both released in response to nutrient ingestion.&#xD;
      Glucagon-like peptide-1 has been demonstrated to augment glucose-dependent insulin secretion;&#xD;
      suppress glucagon release and hepatic gluconeogenesis; inhibit gastric emptying, and reduce&#xD;
      appetite and food intake. Glucagon-like peptide-1 and glucose-dependent insulinotropic&#xD;
      peptide also have been shown to promote insulin biosynthesis and stimulate beta cell&#xD;
      proliferation and survival. Orally available inhibitors of dipeptidyl peptidase-4 activity&#xD;
      have been developed that increase intact postprandial glucagon-like peptide-1 levels after&#xD;
      oral administration.&#xD;
&#xD;
      SYR-472 is a selective inhibitor of dipeptidyl peptidase-4 in development to improve glycemic&#xD;
      control in patients with type 2 diabetes mellitus. The aim of this study is to evaluate&#xD;
      SYR-472 in subjects with type 2 diabetes mellitus who have not previously achieved adequate&#xD;
      glycemic control with lifestyle modification (diet/exercise) or metformin antidiabetic&#xD;
      monotherapy. Study participation is anticipated to be up to 14 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in glycosylated hemoglobin</measure>
    <time_frame>Weeks 12 or Final Visit.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in glycosylated hemoglobin</measure>
    <time_frame>Weeks 4, 8, and 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting plasma glucose</measure>
    <time_frame>Weeks 1, 2, 4, 8, and 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1,5-Anhydroglucitol</measure>
    <time_frame>Weeks 2, 4, 8, and 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Proinsulin</measure>
    <time_frame>Weeks 4, 8, and 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Proinsulin/insulin ratio</measure>
    <time_frame>Weeks 4, 8, and 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in baseline C-peptide</measure>
    <time_frame>Weeks 4, 8, and 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in insulin</measure>
    <time_frame>Weeks 4, 8, and 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Homeostasis model assessment of beta cell function</measure>
    <time_frame>Weeks 4, 8, and 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Homeostasis model assessment of insulin resistance</measure>
    <time_frame>Weeks 4, 8, and 12 or Final Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of rescue</measure>
    <time_frame>Weeks 1, 2, 4, 8, and 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response endpoint incidence of glycosylated hemoglobin less than or equal to 6.5%</measure>
    <time_frame>Week 12 or Final Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response endpoint incidence of glycosylated hemoglobin less than or equal to 7.0%</measure>
    <time_frame>Week 12 or Final Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Fasting lipids (triglycerides, total cholesterol, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol)</measure>
    <time_frame>Weeks 4, 8, and 12 or Final Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>Weeks 4, 8, and 12 or Final Visit.</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">369</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>SYR-472 25 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(with lifestyle modification and/or metformin therapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SYR-472 50 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(with lifestyle modification and/or metformin therapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SYR-472 100 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(with lifestyle modification and/or metformin therapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SYR-472 200 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(with lifestyle modification and/or metformin therapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo QD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>(with lifestyle modification and/or metformin therapy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYR-472</intervention_name>
    <description>SYR-472 25 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.</description>
    <arm_group_label>SYR-472 25 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYR-472</intervention_name>
    <description>SYR-472 50 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.</description>
    <arm_group_label>SYR-472 50 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYR-472</intervention_name>
    <description>SYR-472 100 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.</description>
    <arm_group_label>SYR-472 100 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYR-472</intervention_name>
    <description>SYR-472 200 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.</description>
    <arm_group_label>SYR-472 200 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>SYR-472 placebo-matching tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.</description>
    <arm_group_label>Placebo QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has a historical diagnosis of type 2 diabetes mellitus.&#xD;
&#xD;
          -  Has undergone less than 7 days of any antidiabetic therapy except lifestyle&#xD;
             modification (diet/exercise) within 8 weeks prior to Screening; or has received&#xD;
             metformin monotherapy for at least 8 weeks prior to Screening and maintained a stable&#xD;
             daily dose of metformin for at least 12 weeks prior to randomization.&#xD;
&#xD;
          -  The subject receiving metformin monotherapy at randomization must have been at least&#xD;
             75% compliant with his or her regimen during the Run-in/Stabilization Period as&#xD;
             determined by subject diary and investigator assessment.&#xD;
&#xD;
          -  Has received no treatment with antidiabetic agents other than metformin within the 8&#xD;
             weeks prior to Screening.&#xD;
&#xD;
          -  Has a glycosylated hemoglobin concentration between 7.0% and 10.0%, inclusive, at&#xD;
             Screening and at the Week -1 Visit.&#xD;
&#xD;
          -  The subject's fasting C-peptide concentration is greater than or equal to 0.8 ng/mL.&#xD;
&#xD;
          -  Has a fasting plasma glucose concentration less than 275 mg/dL.&#xD;
&#xD;
          -  If regularly uses other non-excluded medications, must be on a stable dose for at&#xD;
             least the 4 weeks prior to Screening.&#xD;
&#xD;
          -  Has a systolic blood pressure reading less than 160 mm Hg and a diastolic pressure&#xD;
             reading less than 100 mm Hg.&#xD;
&#xD;
          -  Has a hemoglobin value greater than or equal to 12 g/dL for men and greater than or&#xD;
             equal to 10 g/dL for women.&#xD;
&#xD;
          -  Has an alanine aminotransferase level is less than or equal to 3 times the upper limit&#xD;
             of normal.&#xD;
&#xD;
          -  Males have a serum creatinine value less than 1.5 mg/dL; females have a serum&#xD;
             creatinine value less than 1.4 mg/dL.&#xD;
&#xD;
          -  Has a urine albumin/creatinine ratio less than 1000 Î¼g/mg.&#xD;
&#xD;
          -  Has a thyroid-stimulating hormone level less than or equal to the upper limit of the&#xD;
             normal range and is clinically euthyroid.&#xD;
&#xD;
          -  Females must be not be pregnant or lactating, and must agree to use adequate&#xD;
             contraception throughout the duration of the study.&#xD;
&#xD;
          -  Is able and willing to monitor his or her own blood glucose concentrations with a home&#xD;
             glucose monitor.&#xD;
&#xD;
          -  Has no major illness or debility that in the investigator's opinion prohibits the&#xD;
             subject from completing the study.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Is being concurrently treated with antidiabetic therapy other than metformin and&#xD;
             lifestyle intervention.&#xD;
&#xD;
          -  Has a history of cancer, other than squamous cell or basal cell carcinoma of the skin&#xD;
             that has not been in full remission for at least 5 years prior to Screening.&#xD;
&#xD;
          -  Has a history of laser treatment for proliferative diabetic retinopathy within the 6&#xD;
             months prior to Screening.&#xD;
&#xD;
          -  Has a history of treated diabetic gastric paresis.&#xD;
&#xD;
          -  Has New York Heart Association class III or IV heart failure regardless of therapy.&#xD;
&#xD;
          -  Has a history of coronary angioplasty, underwent coronary stent placement or coronary&#xD;
             bypass surgery, or suffered a myocardial infarction, or stroke within the 6 months&#xD;
             prior to Screening.&#xD;
&#xD;
          -  Has a history of any hemoglobinopathy that may affect determination of glycosylated&#xD;
             hemoglobin.&#xD;
&#xD;
          -  Has a history of infection with human immunodeficiency virus.&#xD;
&#xD;
          -  Has a history of a psychiatric disorder that in the investigator's opinion will affect&#xD;
             the subject's ability to participate in the study.&#xD;
&#xD;
          -  Has ingested or received systemically injected glucocorticoids within the 3 months&#xD;
             prior to randomization. Inhaled corticosteroids are allowed.&#xD;
&#xD;
          -  Has used prescription or over-the-counter weight-loss drugs within the 3 months prior&#xD;
             to randomization.&#xD;
&#xD;
          -  Has received any investigational drug within the 30 days prior to Screening or has&#xD;
             received an investigational antidiabetic drug within the 3 months prior to Screening.&#xD;
&#xD;
          -  Has received previous treatment in an investigational study of SYR-472.&#xD;
&#xD;
          -  Has a known hypersensitivity to any compound related to SYR-472.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pell City</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallassee</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sierra Vista</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>National City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pismo Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dawsonville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Slidell</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taunton</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scottsbluff</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sparta</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bensalem</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Central Point</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clemson</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Richland Hills</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spring</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sugarland</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hampton</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quetzaltenango</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eger</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szentes</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sigulda</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valmiera</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kedainiai</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ponce</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alba Iulia</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baia Mare</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bihor</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Constanta</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ploiesti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Satu Mare</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Targoviste</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Volgograd</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Presov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vinnytsya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>April 1, 2008</study_first_submitted>
  <study_first_submitted_qc>April 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2008</study_first_posted>
  <disposition_first_submitted>June 20, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>June 20, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 22, 2016</disposition_first_posted>
  <last_update_submitted>June 20, 2016</last_update_submitted>
  <last_update_submitted_qc>June 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glucose Metabolism Disorder</keyword>
  <keyword>Dysmetabolic Syndrome</keyword>
  <keyword>Type II Diabetes</keyword>
  <keyword>Diabetes Mellitus, Lipoatrophic</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Hyperglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

